Transcriptome analysis for the effect of Trichostatin A on intrahepatic cholangiocarcinoma cells
Trichostatin A (TSA) is a commonly used antifungal drug characterized by inhibiting the activity of histone deacetylases (HDACs). As an antineoplastic agent, the pharmacological actions of TSA includes: 1. Inhibiting the proliferation of tumor cells directly; 2. Promoting the antitumor effect of immune cells; 3. Enhancing the efficacy of other antitumor drugs. The efficacy of TSA in the treatment of intrahepatic cholangiocarcinoma (ICCA) is still unknown and needs further verification. Therefore, in this study, ICCA cell line HUCCT1 was treated by TSA. The total RNA samples were used for transcriptome analysis to find the potential target of HDACs. Overall design: This dataset included two groups of samples. Every group contained three repetitions (rep). TSA was dissolved in DMSO. HUCCT1 cells were treated by TSA (0.5 µM) for 24h. Another group of HUCCT cells underwent the same treatment with DMSO.  The total RNA was extracted and used for RNA-seq.